Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pseudoephedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 2/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.81 |
| ▸ | HTR2A | P28223 | 2/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.81 |
| ▸ | RGS12 | O14924 | 1/20 | 0.81 |
| ▸ | GLA | P06280 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | PKM | P14618 | 1/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.81 |
| ▸ | THPO | P40225 | 1/20 | 0.81 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pseudoephedrine SCHEMBL4780816 | 1.00 | ADRA2C (0.81) | ADRA2CADRA1AHTR2ACHRM2RGS12 | |
| Ephedrine SCHEMBL9641985 | 1.00 | ADRA2C (0.81) | ADRA2CADRA1AHTR2ACHRM2RGS12 | |
| Pseudoephedrine SCHEMBL9390910 | 0.98 | KMT2A (0.82) | ADRA2CADRA1AHTR2ACHRM2RGS12 | |
| Racephedrine SCHEMBL28739755 | 0.90 | ADRA2C (0.92) | ADRA2CADRA1AHTR2ACHRM2RGS12 | |
| Ephedrine SCHEMBL4731265 | 0.90 | CYP2D6 (1.00) | ADRA2CADRA1AHTR2ACHRM2RGS12 | |
| Racephedrine SCHEMBL11906521 | 0.90 | CYP2D6 (1.00) | ADRA2CADRA1AHTR2ACHRM2RGS12 | |
| Racephedrine SCHEMBL12573578 | 0.90 | CYP2D6 (1.00) | ADRA2CADRA1AHTR2ACHRM2RGS12 | |
| Racephedrine SCHEMBL8098202 | 0.90 | CYP2D6 (1.00) | ADRA2CADRA1AHTR2ACHRM2RGS12 | |
| Racephedrine SCHEMBL4786 | 0.90 | CYP2D6 (1.00) | ADRA2CADRA1AHTR2ACHRM2RGS12 | |
| Pseudoephedrine SCHEMBL4368 | 0.90 | CYP2D6 (1.00) | ADRA2CADRA1AHTR2ACHRM2RGS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246668-A1 | AN RAPID ACTING FREEZE DIRED ORAL PHARMACEUTICAL COMPOSITION FOR TREATING MIGRAINE | Natco Pharma Limited (IN) | 2002-10-09 | — | — | EP | claimed |
| WO-2001039836-A1 | A RAPID ACTING FREEZE DIRED ORAL PHARMACEUTICAL COMPOSITION FOR TREATING MIGRAINE | NATCO PHARMA LIMITED (IN) | 2001-06-07 | — | — | WO | claimed |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | METABASIS THERAPEUTICS INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS INC. | 2018-12-06 | — | — | US | disclosed |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS, INC. | 2017-11-09 | — | — | US | disclosed |
| WO-2017184811-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170112864-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | METABASIS THERAPEUTICS, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| CN-104010630-A | Pharmaceutical dosage form comprising poly (epsilon-caprolactone) and polyoxyethylene | PURDUE PHARMA LP | 2014-08-27 | — | — | CN | disclosed |
| US-20010051657-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | PFIZER INC. | 2001-12-13 | — | — | US | disclosed |
| US-20010051645-A1 | Thyroid receptor ligands | CHIANG YUAN-CHING P (US) | 2001-12-13 | — | — | US | disclosed |
| EP-1148054-A1 | Thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001072692-A1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-1127882-A1 | Tetrazole compounds as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1125579-A2 | Uses of agrp-melanocortin receptor binding modulating compounds | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001056574-A1 | USE OF DESLORATADINE FOR TREATING ALLERGIC AND INFLAMMATORY CONDITIONS | SCHERING CORPORATION (US) | 2001-08-09 | — | — | WO | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1088819-A2 | 6-azauracil derivatives as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112864-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | TSHR, THRA, FABP1 | ADRA2C 295/4885ADRA1A 478/4885HTR2A 899/4885 |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | THRB, THRA, TSHR | ADRA2C 154/4885ADRA1A 138/4885HTR2A 699/4885 |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | ADRA2C 295/4885ADRA1A 478/4885HTR2A 899/4885 |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | TSHR, THRA, FABP1 | ADRA2C 284/4885ADRA1A 459/4885HTR2A 896/4885 |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | ADRA2C 154/4885ADRA1A 138/4885HTR2A 699/4885 |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | ADRA2C 154/4885ADRA1A 138/4885HTR2A 699/4885 |
| US-20010051645-A1 | Thyroid receptor ligands | TSHR, THRB, THRA | ADRA2C 197/4885ADRA1A 181/4885HTR2A 624/4885 |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | ADRA2C 295/4885ADRA1A 478/4885HTR2A 899/4885 |
| US-20010051657-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, THRB | ADRA2C 1705/4885ADRA1A 622/4885HTR2A 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.